UroGen Pharma (URGN) Competitors $10.64 -0.07 (-0.65%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends URGN vs. AVDL, BCYC, COLL, SEPN, BCAX, ZYME, GYRE, PSTX, PAHC, and COGTShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Avadel Pharmaceuticals Bicycle Therapeutics Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Cogent Biosciences UroGen Pharma (NASDAQ:URGN) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Do analysts rate URGN or AVDL? UroGen Pharma presently has a consensus target price of $43.70, suggesting a potential upside of 310.71%. Avadel Pharmaceuticals has a consensus target price of $24.43, suggesting a potential upside of 136.94%. Given UroGen Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe UroGen Pharma is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor URGN or AVDL? UroGen Pharma received 23 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 73.89% of users gave UroGen Pharma an outperform vote while only 66.02% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes36573.89% Underperform Votes12926.11% Avadel PharmaceuticalsOutperform Votes34266.02% Underperform Votes17633.98% Which has more volatility and risk, URGN or AVDL? UroGen Pharma has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Does the media prefer URGN or AVDL? In the previous week, Avadel Pharmaceuticals had 8 more articles in the media than UroGen Pharma. MarketBeat recorded 8 mentions for Avadel Pharmaceuticals and 0 mentions for UroGen Pharma. Avadel Pharmaceuticals' average media sentiment score of 1.20 beat UroGen Pharma's score of 0.00 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment UroGen Pharma Neutral Avadel Pharmaceuticals Positive Is URGN or AVDL more profitable? Avadel Pharmaceuticals has a net margin of -52.53% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Avadel Pharmaceuticals -52.53%-93.34%-44.77% Which has preferable earnings and valuation, URGN or AVDL? UroGen Pharma has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$89.36M2.79-$102.24M-$3.15-3.38Avadel Pharmaceuticals$138.16M7.19-$160.28M-$0.79-13.05 Do insiders and institutionals hold more shares of URGN or AVDL? 91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by company insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryUroGen Pharma beats Avadel Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$249.55M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-3.3810.5090.8717.14Price / Sales2.79195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book-3.835.104.784.78Net Income-$102.24M$151.51M$119.77M$225.60M7 Day Performance-6.26%-2.12%-1.87%-1.23%1 Month Performance-8.35%-3.11%11.46%3.07%1 Year Performance-29.40%11.52%30.49%16.48% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma3.8621 of 5 stars$10.64-0.7%$43.70+310.7%-28.4%$249.55M$89.36M-3.38200High Trading VolumeAVDLAvadel Pharmaceuticals2.6643 of 5 stars$10.97+5.6%$24.43+122.7%-24.0%$1.06B$138.16M-13.15154Positive NewsBCYCBicycle Therapeutics3.5984 of 5 stars$15.30+10.8%$36.00+135.3%-18.8%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeCOLLCollegium Pharmaceutical3.8334 of 5 stars$30.63+1.8%$42.60+39.1%-0.4%$987.82M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2145 of 5 stars$21.76-2.8%$43.67+100.7%N/A$966.14MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.53+0.2%$43.00+145.3%N/A$953.91MN/A0.0032Gap DownZYMEZymeworks2.8309 of 5 stars$13.82+9.9%$18.83+36.3%+52.5%$951.92M$76.01M-9.25290Analyst ForecastNews CoverageGap DownGYREGyre Therapeutics0.6035 of 5 stars$10.03+4.0%N/A-61.2%$938.02M$105.03M0.0040News CoveragePositive NewsPSTXPoseida Therapeutics3.7439 of 5 stars$9.50-0.1%$9.50+193.5%$928.82M$64.70M-15.10260Positive NewsPAHCPhibro Animal Health4.1177 of 5 stars$22.76+0.4%$19.00-16.5%+89.6%$921.85M$1.05B52.561,940Analyst ForecastCOGTCogent Biosciences1.9517 of 5 stars$8.22+0.9%$14.83+80.5%+51.9%$907.98MN/A-3.2980 Related Companies and Tools Related Companies Avadel Pharmaceuticals Competitors Bicycle Therapeutics Competitors Collegium Pharmaceutical Competitors Septerna Competitors Bicara Therapeutics Competitors Zymeworks Competitors Gyre Therapeutics Competitors Poseida Therapeutics Competitors Phibro Animal Health Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:URGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts